Compounded Semaglutide: Safety, Regulation & When It Still Makes Sense
1. From Shortage Boom to Policy Whiplash A national Ozempic®/Wegovy® shortage in 2022–24 opened the floodgates for 503A/503B pharmacies to compound semaglutide. On Feb 21 2025 the FDA formally declared the shortage resolved, citing Novo Nordisk data showing supply now meets or exceeds demand. Because compounding is only permitted when an FDA-approved drug is “not…
Details











